Don’t panic, Albendazole is safe for deworming, says Nadda
New Delhi: Union Minister for Health and Family Welfare J.P. Nadda said Albendazole is a “safe and effective” drug for the treatment of parasitic worms, adding that it is approved by the World Health Organisation (WHO) and used globally.
Nadda’s statement came in the wake of media reports regarding some children complaining of nausea, gastric irritation and giddiness on being administered Albendazole tablets as part of the nationwide deworming initiative.
“Of a target of 27 crore children, 236 from Bihar, Chattisgarh, Haryana, Maharashtra and Rajasthan reported some mild adverse effect. The children were hospitalised, kept under observation and discharged without any major or serious complications. This is as per our standard protocol,” said the minister.
“There is no need to panic,” he said, “as such adverse incidences are noticed when the worm load is high among the children. However, care needs to be taken that the children are administered the drug in presence of teachers or guardians.”
National Deworming Day, a flagship initiative of the Ministry of Health and Family Welfare, was observed on February 10. It is the largest ever single-day public health campaign in the world targeting approximately 27 crore children aged 1-19 years throughout the country at risk of parasitic worm infection through the platform of schools and anganwadi centres.
The target population includes 8 crore children in the age group of 1-5 years and 19 crore children in the age group of 6-19 years across 561 districts of the country.
Over 900,000 education and health workers administered Albendazole tablet to crores of children in schools and anganwadis across India on Wednesday.
As many as 137 districts in 14 states have been excluded from the deworming initiative this year, as they have already covered during Mass Drug Administration in Lyphatic Filarsis programme of the Health Ministry.
Robust systems of monitoring have been instated and health workers trained to administer the deworming tablets.
Nadda’s statement came in the wake of media reports regarding some children complaining of nausea, gastric irritation and giddiness on being administered Albendazole tablets as part of the nationwide deworming initiative.
“Of a target of 27 crore children, 236 from Bihar, Chattisgarh, Haryana, Maharashtra and Rajasthan reported some mild adverse effect. The children were hospitalised, kept under observation and discharged without any major or serious complications. This is as per our standard protocol,” said the minister.
“There is no need to panic,” he said, “as such adverse incidences are noticed when the worm load is high among the children. However, care needs to be taken that the children are administered the drug in presence of teachers or guardians.”
National Deworming Day, a flagship initiative of the Ministry of Health and Family Welfare, was observed on February 10. It is the largest ever single-day public health campaign in the world targeting approximately 27 crore children aged 1-19 years throughout the country at risk of parasitic worm infection through the platform of schools and anganwadi centres.
The target population includes 8 crore children in the age group of 1-5 years and 19 crore children in the age group of 6-19 years across 561 districts of the country.
Over 900,000 education and health workers administered Albendazole tablet to crores of children in schools and anganwadis across India on Wednesday.
As many as 137 districts in 14 states have been excluded from the deworming initiative this year, as they have already covered during Mass Drug Administration in Lyphatic Filarsis programme of the Health Ministry.
Robust systems of monitoring have been instated and health workers trained to administer the deworming tablets.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.